D-Index & Metrics Best Publications
Research.com 2022 Best Female Scientist Award Badge

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 117 Citations 62,033 580 World Ranking 1780 National Ranking 19
Best female scientists D-index 117 Citations 62,307 673 World Ranking 372 National Ranking 3

Research.com Recognitions

Awards & Achievements

2022 - Research.com Best Female Scientist Award

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Martine Piccart mainly investigates Internal medicine, Breast cancer, Oncology, Surgery and Chemotherapy. Her Internal medicine research focuses on subjects like Gynecology, which are linked to Performance status and Randomized controlled trial. Her work deals with themes such as Chemotherapy regimen, Disease and Gene expression profiling, which intersect with Breast cancer.

Her Oncology research includes themes of Trastuzumab, Anthracycline, Estrogen receptor, Exemestane and Adjuvant therapy. Her Surgery research is multidisciplinary, incorporating perspectives in Hormonal therapy, Adverse effect and Ovarian cancer. Martine Piccart has included themes like Gastroenterology and Regimen in her Chemotherapy study.

Her most cited work include:

  • Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer (2040 citations)
  • Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis (1946 citations)
  • Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis (1574 citations)

What are the main themes of her work throughout her whole career to date?

Her main research concerns Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. Her Internal medicine research is multidisciplinary, relying on both Gastroenterology and Surgery. The concepts of her Breast cancer study are interwoven with issues in Cancer research and Disease, Pathology.

Her research in Oncology tackles topics such as Anthracycline which are related to areas like Taxane. Her Cancer study incorporates themes from MEDLINE and Intensive care medicine. The Chemotherapy study combines topics in areas such as Regimen and Ovarian cancer.

She most often published in these fields:

  • Internal medicine (69.77%)
  • Breast cancer (65.12%)
  • Oncology (57.99%)

What were the highlights of her more recent work (between 2017-2021)?

  • Internal medicine (69.77%)
  • Breast cancer (65.12%)
  • Oncology (57.99%)

In recent papers she was focusing on the following fields of study:

The scientist’s investigation covers issues in Internal medicine, Breast cancer, Oncology, Trastuzumab and Cancer. Her study in Chemotherapy, Metastatic breast cancer, Hazard ratio, Pertuzumab and Early breast cancer is carried out as part of her studies in Internal medicine. Her research integrates issues of Cancer research, Clinical endpoint, Clinical trial, Disease and Radiation therapy in her study of Breast cancer.

She specializes in Oncology, namely Adjuvant. Martine Piccart interconnects Neoadjuvant therapy and Proportional hazards model in the investigation of issues within Trastuzumab. Her Cancer research focuses on Aromatase inhibitor in particular.

Between 2017 and 2021, her most popular works were:

  • Long-term outcomes for neoadjuvant versus adjuvant chemotherapy in early breast cancer: meta-analysis of individual patient data from ten randomised trials (340 citations)
  • Tumor-Infiltrating Lymphocytes and Prognosis: A Pooled Individual Patient Analysis of Early-Stage Triple-Negative Breast Cancers (216 citations)
  • Unravelling triple-negative breast cancer molecular heterogeneity using an integrative multiomic analysis. (110 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Gene

Her primary areas of study are Internal medicine, Breast cancer, Oncology, Chemotherapy and Trastuzumab. Martine Piccart is interested in Letrozole, which is a field of Breast cancer. Her study in the field of Adjuvant also crosses realms of In patient.

Her Chemotherapy research integrates issues from Meta-analysis, Immunotherapy, Anthracycline and Early breast cancer. Her Trastuzumab research incorporates themes from Mastectomy, Breast surgery and Circulating tumor cell. Her Clinical trial research is multidisciplinary, incorporating elements of Cancer and Randomized controlled trial.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast Cancer

José Baselga;Mario Campone;Martine Piccart;Howard A. Burris.
The New England Journal of Medicine (2012)

2777 Citations

Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis

Patricia Cortazar;Lijun Zhang;Michael Untch;Keyur Mehta.
The Lancet (2014)

2460 Citations

A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer

Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert.
The New England Journal of Medicine (2003)

2258 Citations

Gene Expression Profiling in Breast Cancer: Understanding the Molecular Basis of Histologic Grade To Improve Prognosis

Christos Sotiriou;Pratyaksha Wirapati;Sherene Loi;Adrian Harris.
Journal of the National Cancer Institute (2006)

1952 Citations

Comparisons between different polychemotherapy regimens for early breast cancer: meta-analyses of long-term outcome among 100,000 women in 123 randomised trials.

R Peto;C Davies;J Godwin.
The Lancet (2012)

1574 Citations

Validation and Clinical Utility of a 70-Gene Prognostic Signature for Women With Node-Negative Breast Cancer

Marc Buyse;Sherene Loi;Laura van't Veer;Giuseppe Viale.
Journal of the National Cancer Institute (2006)

1373 Citations

Randomized Trial of Letrozole Following Tamoxifen as Extended Adjuvant Therapy in Receptor-Positive Breast Cancer: Updated Findings from NCIC CTG MA.17

Paul E. Goss;James N. Ingle;Silvana Martino;Nicholas J. Robert.
Journal of the National Cancer Institute (2005)

1347 Citations

Randomized Intergroup Trial of Cisplatin–Paclitaxel Versus Cisplatin–Cyclophosphamide in Women With Advanced Epithelial Ovarian Cancer: Three-Year Results

Martine J. Piccart;Kamma Bertelsen;Keith James;Jim Cassidy.
Journal of the National Cancer Institute (2000)

1183 Citations

70-Gene Signature as an Aid to Treatment Decisions in Early-Stage Breast Cancer

Fatima Cardoso;Laura J. van’t Veer;Jan Bogaerts;Leen Slaets.
The New England Journal of Medicine (2016)

1128 Citations

Strong time dependence of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multicenter independent validation series,

Christine Desmedt;Fanny Piette;Sherene Loi;Yixin Wang.
Clinical Cancer Research (2007)

1021 Citations

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Martine Piccart

Gabriel N. Hortobagyi

Gabriel N. Hortobagyi

The University of Texas MD Anderson Cancer Center

Publications: 151

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 149

Lajos Pusztai

Lajos Pusztai

Yale University

Publications: 144

Sherene Loi

Sherene Loi

Peter MacCallum Cancer Centre

Publications: 143

Nadia Harbeck

Nadia Harbeck

Ludwig-Maximilians-Universität München

Publications: 140

Christos Sotiriou

Christos Sotiriou

Université Libre de Bruxelles

Publications: 138

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 138

Jonas Bergh

Jonas Bergh

Karolinska Institute

Publications: 136

Fabrice Andre

Fabrice Andre

Institut Gustave Roussy

Publications: 132

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 126

Giuseppe Viale

Giuseppe Viale

European Institute of Oncology

Publications: 125

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 117

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 115

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 115

Mitch Dowsett

Mitch Dowsett

Breast Cancer Research Foundation

Publications: 114

Jorge S. Reis-Filho

Jorge S. Reis-Filho

Memorial Sloan Kettering Cancer Center

Publications: 110

Trending Scientists

Keikichi Hirose

Keikichi Hirose

University of Tokyo

Takashi Hisatomi

Takashi Hisatomi

Shinshu University

Renxian Zhou

Renxian Zhou

Zhejiang University

Darrin J. Pochan

Darrin J. Pochan

University of Delaware

Takeshi Yanagida

Takeshi Yanagida

University of Tokyo

Philip E. Auron

Philip E. Auron

Duquesne University

Salit Kark

Salit Kark

University of Queensland

Jeffrey S. Rubin

Jeffrey S. Rubin

National Institutes of Health

Andrej Trampuz

Andrej Trampuz

Charité - University Medicine Berlin

Cheol-In Kang

Cheol-In Kang

Samsung Medical Center

David Russo

David Russo

Agricultural Research Organization

John C. Gille

John C. Gille

National Center for Atmospheric Research

Niall P. McNamara

Niall P. McNamara

UK Centre for Ecology & Hydrology

Judy A. Andrews

Judy A. Andrews

Oregon Research Institute

Hiroshi Demura

Hiroshi Demura

Tohoku University

Torbjörn Falkmer

Torbjörn Falkmer

Curtin University

Something went wrong. Please try again later.